HC Wainwright Increases Rani Therapeutics (NASDAQ:RANI) Price Target to $13.00

Rani Therapeutics (NASDAQ:RANI) had its price target boosted by equities research analysts at HC Wainwright from $12.00 to $13.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 81.82% from the company’s current price.

Several other research analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Rani Therapeutics in a report on Tuesday, February 6th. Canaccord Genuity Group cut their price objective on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.75.

Rani Therapeutics Stock Down 4.2 %

Shares of RANI stock opened at $7.15 on Tuesday. The stock’s 50 day simple moving average is $4.65 and its 200 day simple moving average is $3.51. Rani Therapeutics has a twelve month low of $1.82 and a twelve month high of $8.75. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.36 and a current ratio of 6.36. The company has a market capitalization of $358.64 million, a price-to-earnings ratio of -5.56 and a beta of 0.33.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. As a group, research analysts predict that Rani Therapeutics will post -0.94 EPS for the current year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.